top of page

BridgeBio Founder and CEO Neil Kumar discusses the approval of Attruby and the company's commercialization plans

  • blonca9
  • Nov 25, 2024
  • 1 min read

He describes the label and what he believes it means for the therapy's competitive position. Plus, the commercial plans that have put into place, and three key trial readouts to watch over the next year.



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter
  • LinkedIn
  • Facebook
  • TikTok
  • Instagram

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

evaluate-logo-png_seeklogo-457165-2_edited.png

Evaluate is a trusted provider of forecasting and commercial intelligence to the pharmaceutical industry. With a combination of gold standard data sources and deep pharma expertise, Evaluate helps clients make the right portfolio decisions to drive growth.

Evaluate's solutions provide a complete, dynamic view of development risk and commercial return across the full clinical lifecycle, underpinned by consensus forecasts to 2032, pipelines, deals and more. A consulting and analytics team is on always hand to help clients address unique clinical and commercial challenges.

bottom of page